Integrative Transcriptomics Uncovers **IFN-β**-Induced **43-Gene Signature** and **IFITM3** as Key Mediator in **Multiple Sclerosis**
Integrative Transcriptomics Uncovers IFN-β Signature and IFITM3 as Putative Molecular Mediator in MS.
Background
Multiple sclerosis (MS) is a complex neuroinflammatory disease driven by myelin-reactive T cell infiltration into the central nervous system (CNS). While Interferon-β (IFN-β) is one of the earliest disease-modifying treatments (DMTs) approved for MS, its precise mechanism of action and reliable biomarkers for treatment response remain largely undefined. Understanding the molecular pathways modulated by IFN-β is crucial for optimizing its use and developing new therapeutic strategies, especially for populations like pregnant and elderly patients where its favorable safety profile is valued.